These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15170763)

  • 1. Application of a propensity score to adjust for channelling bias with NSAIDs.
    Morant SV; Pettitt D; MacDonald TM; Burke TA; Goldstein JL
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):345-53. PubMed ID: 15170763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
    MacDonald TM; Morant SV; Goldstein JL; Burke TA; Pettitt D
    Gut; 2003 Sep; 52(9):1265-70. PubMed ID: 12912856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
    MacDonald TM; Pettitt D; Lee FH; Schwartz JS
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii3-10. PubMed ID: 14585912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
    Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam.
    Curtiss FR
    J Manag Care Pharm; 2006 Apr; 12(3):265-8. PubMed ID: 16623613
    [No Abstract]   [Full Text] [Related]  

  • 11. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
    Jick SS
    Pharmacotherapy; 2000 Jul; 20(7):741-4. PubMed ID: 10907963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
    Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
    Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The selective cox-2 inhibitor meloxicam and salicylate therapy].
    Tóth K
    Ideggyogy Sz; 2005 May; 58(5-6):173-4. PubMed ID: 16021964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Meloxicam--the balance of efficacy and safety].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):85-6. PubMed ID: 19024285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meloxicam--a safer NSAID?
    Drug Ther Bull; 1998 Aug; 36(8):62-4. PubMed ID: 9876404
    [No Abstract]   [Full Text] [Related]  

  • 18. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.
    Martin RM; Biswas P; Mann RD
    Br J Clin Pharmacol; 2000 Jul; 50(1):35-42. PubMed ID: 10886116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
    Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.